<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162643</url>
  </required_header>
  <id_info>
    <org_study_id>SALUD-2003-C01-123</org_study_id>
    <nct_id>NCT00162643</nct_id>
  </id_info>
  <brief_title>PI Vs. NNRTI Based Therapy for HIV Advanced Disease</brief_title>
  <official_title>Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <brief_summary>
    <textblock>
      Ritonavir boosted protease inhibitor based therapy will have equivalent antiviral efficacy
      over 48 weeks compared to NNRTI based therapy in patients who are antiretroviral therapy
      naïve and initiate therapy with CD4 counts ≤ 200/mm3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guidelines for initial therapy in HIV infection recommend 2 NRTIs plus either a
      ritonavir boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor
      (NNRTI). Recent data suggests that the rate of response to PI based therapy may be slightly
      compromised if the baseline CD4 count is ≤ 200/mm3 and the plasma HIV-1-RNA ≥ 100,000
      copies/mL. This may not be equally apparent if ritonavir boosted protease inhibitors are
      used. The effect of baseline CD4 count and HIV-1-RNA levels on the antiviral efficacy of
      NNRTI based regimens has been less well characterized. A significant number of patients
      currently initiate therapy at late stages of progression, typically with baseline CD4 count
      is ≤ 200/mm3. In Mexico approximately 60% of patients who initiate therapy are within this
      range of CD4 cell counts. Currently, the two combinations recommended as preferred are with
      two NRTIs and either Efavirenz or Lopinavir/ritonavir, while other combinations of PIs and
      ritonavir are considered alternative.

      Comparison: The efficacy of ritonavir boosted protease inhibitor based therapy versus NNRTI
      based therapy in patients who are antiretroviral therapy naïve and initiate therapy with a
      CD4 count ≤ 200/mm3.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who reach HIV-1-RNA ≤ 50 copies/mL at 48 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma Viral Load change from baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine+lamivudine+lopinavir/ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine + lamivudine + efavirenz</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected individuals

          -  Men or women at least 18 years old

          -  CD4+ T cells ≤200/ml

          -  Antiretroviral naive

        Exclusion Criteria:

          -  Suspected or documented active, untreated HIV 1 related opportunistic infection (OI)
             or other condition requiring acute therapy (e.g., hepatitis C virus infection)

          -  Platelet count &lt; 75,000 cells/mm3.

          -  Hemoglobin &lt; 9 g/dL .

          -  AST and/or ALT greater than 5 times the upper limit of normal

          -  Documented or suspected active tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan G Sierra-Madero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan G Sierra-Madero, MD</last_name>
    <phone>5255-56559675</phone>
    <email>jsmadero@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelina Villasis-Keever, MD MSc</last_name>
    <phone>5255-56559675</phone>
    <email>avkeever@prodigy.net.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Especialidades Centro Medico Nacional siglo XXI</name>
      <address>
        <city>Mexico City</city>
        <state>D.f.</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia M Perez-Saleme, MD</last_name>
      <phone>5255-56-27 69 00</phone>
      <phone_ext>21547</phone_ext>
      <email>lepesa@prodigy.net.mx</email>
    </contact>
    <investigator>
      <last_name>Leticia M Perez-Saleme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Villasis-Keever, MD MSc</last_name>
      <phone>5255-56559675</phone>
      <email>avkeever@prodigy.net.mx</email>
    </contact>
    <contact_backup>
      <last_name>Luis E. Soto-Ramirez, MD</last_name>
      <phone>5255-56559675</phone>
      <email>lsoto@quetzal.innsz.mx</email>
    </contact_backup>
    <investigator>
      <last_name>Angelina Villasis-Keever, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis E Soto-Ramirez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Regional #53</name>
      <address>
        <city>Los Reyes La Paz</city>
        <state>Estado de Mexico</state>
        <zip>56400</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Mendez-Cardos, MD</last_name>
      <phone>5255-5855 4414</phone>
      <phone_ext>238</phone_ext>
      <email>kalekbuda74@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Mendez-Cardos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Regional #72</name>
      <address>
        <city>Tlalnepantla</city>
        <state>Estado de Mexico</state>
        <zip>54000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Gutierrez-Escolano, MD MSc</last_name>
      <phone>5255-5565 9210</phone>
      <phone_ext>320</phone_ext>
      <email>fernandamx@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Pueblito Pizano-Gonzalez, MD</last_name>
      <phone>5255-5565 9210</phone>
      <phone_ext>320</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Fernanda Gutierrez-Escolano, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pueblito Pizano-Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Regional de Leon</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan L Mosqueda-Gomez, MD</last_name>
      <phone>5255-4771310037</phone>
      <email>luis_mosqueda@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Juan L Mosqueda-Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>September 13, 2006</last_update_submitted>
  <last_update_submitted_qc>September 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2006</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiretroviral Therapy, Highly Active</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

